Data compiled by Redley Lamar · ChainSifter Intelligence
1Suppliers
6Customers
3Debt Items
20Related Chains
Source-Backed Evidence Depth
Forte Biosciences, Inc. (FBRX) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
11Total relationships
2Distinct source URLs
6High confidence
0.793Average confidence
2026-09-13Latest database update
ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.
Forte Biosciences, Inc. Suppliers
Ticker
Name
Confidence
Evidence
CLINICAL-RESEARCH-ORGANIZATION
CLINICAL-RESEARCH-ORGANIZATION
92%
The Company entered into agreements with a clinical research organization ("CRO") for clinical trials of FB102, its product candidate.
Forte Biosciences, Inc. Customers
Ticker
Name
Confidence
Evidence
ARGENX-BV
ARGENX-BV
90%
As part of the Offering, argenx BV has made a strategic investment in the Company.
SNYNF
Sanofi
72%
Reciprocal relationship from SNYNF graph: Reciprocal relationship from FBRX graph: most significantly China, with respect to trade policies, treaties, tariffs, taxes, and other limitations on cross-b…
SNYNF
Sanofi
72%
most significantly China, with respect to trade policies, treaties, tariffs, taxes, and other limitations on cross-border operations. The U.S. government has made and continues to make significant ad…
LEGAL-PROCEEDINGS-FORTE-BIOSCIENCES-INC
LEGAL-PROCEEDINGS-FORTE-BIOSCIENCES-INC
62%
vable, or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for in…
PALMS-INSURANCE-COMPANY
PALMS-INSURANCE-COMPANY
62%
were $2.0 million for the three months ended March 31, 2026 compared to $3.4 million for the same period in 2025. The decrease was primarily due to the interim legal settlement payment, under a reser…
SILVERGATE-CAPITAL-CORP
SILVERGATE-CAPITAL-CORP
62%
nificantly China, with respect to trade policies, treaties, tariffs, taxes, and other 43 limitations on cross-border operations. The U.S. government has made and continues to make significant additio…
Forte Biosciences, Inc. Debt Obligations
Instrument
Description
Confidence
Evidence
FBRX-DEBT
Debt stack $22.1M
90%
Market cache reports total debt of $22.1M.
FBRX-DEBT-9444
Xbrl Convertible
90%
xbrl convertible detail from xbrl 2020-12-31.
FBRX-DEBT-9443
Warrants outstanding: 479000
90%
xbrl warrant detail from xbrl 2025-06-30.
Forte Biosciences, Inc. Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for Forte Biosciences, Inc..
Forte Biosciences, Inc. Ownership
Holder
Name
Confidence
Evidence
FBRX-OWNER-JANUS-HENDERSON-GROUP-PLC
JANUS HENDERSON GROUP PLC
90%
13F overlay lists JANUS HENDERSON GROUP PLC as top holder; 70 tracked holders.
Forte Biosciences, Inc. Extended Supply Chain Network
